Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today provides an update on the tradipitant development program.

Exelixis, Inc. (Nasdaq: EXEL) today announced results from a subgroup analysis of the phase 3 CABINET pivotal study of ...

It wasn’t until the first time that I saw someone else with vitiligo in person that my perception changed. This stranger didn’t seem to have a care in the world about his spots. He seemed so ...

The Well+Good editors are finding joy where they find it. Shop the products that invited more delight into their lives.

The logo of Calico is seen on a screen ... or improve respiratory function and quality of life better than the placebo group. However, an “exploratory” high dose of the drug appeared to ...

Met primary endpoint of safety and tolerability in CCM patients with no treatment-related discontinuations or Grade 3 adverse ...

Eli Lilly expects to read out results from a study in people with obesity and osteoarthritis of the knee in 2025.

Drinking ketones improves heart health, a new small-scale study from the University of Portsmouth has found. This is the first time people with type 2 diabetes (T2D) have been given a drink with ...

Primary endpoint met, GH001 led to an ultra-rapid anti-depressant effect with a significant placebo-adjusted MADRS reduction from baseline of ...